December 19, 2018 08:19 AM EST

With cancer in focus, Amgen taps Molecular Partners' preclinical immune-oncology asset for $50M upfront

Amgen $AMGN is vying for a bigger BiTE in cancer, with a pact worth up to $547 million with Molecular Partners for the biotech’ …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With can­cer in fo­cus, Am­gen taps Mol­e­c­u­lar Part­ner­s' pre­clin­i­cal im­mune-on­col­o­gy as­set for $50M up­front